DermTech (DMTK) Misses Q1 EPS by 11c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to DermTech (DMTK) Misses Q1 EPS by 11c

DermTech Reports First-Quarter 2023 Financial Results

May 4, 2023 4:01 PM EDT

- Covered lives increased to 126 million
- Cash runway through the third quarter of 2024

SAN DIEGO--(BUSINESS WIRE)-- DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported its first-quarter 2023 financial results.

In the last few months, we had excellent overall progress with payers and strong execution by our commercial organization, said John Dobak, M.D., CEO, DermTech. We expanded coverage for the DermTech Melanoma Test (DMT) by nearly 40 percent since the end of 2022. Payer... More